Scientists dive deep into immune secrets of ARDS to unlock future treatments
NCT ID NCT07395076
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to better understand why some patients with ARDS (a severe lung condition) get very sick while others recover. Researchers will collect blood and lung fluid from 50 ICU patients to study their immune cells and inflammation patterns. The goal is to identify different patient types so that future treatments can be more personalized and effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
May 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Hospitalized patients in intensive care unit suffering from mechanically ventilated ARDS as defined by Matthay et al.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ARDS risk factors: bacterial or viral pneumonia, extrapulmonary infection, major trauma, transfusion, inhalation injury, or shock. * Pulmonary edema not explained by a cardiogenic cause or volume overload. * Onset of respiratory symptoms within \<7 days. * Bilateral pulmonary involvement on chest X-ray, CT scan, or ultrasound. * PaO₂/FiO₂ ≤ 300 assessed with PEEP ≥ 5 cmH₂O. Exclusion Criteria: * ARDS with intubation for more than 48 hours. * Contraindications to bronchoscopy: effective anticoagulation, dual antiplatelet therapy, thrombocytopenia \<50 G/L. * Pre-existing immunodeficiency: active solid tumor or remission \<5 years, active hematologic malignancy or remission \<5 years, systemic disease (even without specific treatment), solid organ or bone marrow transplant, HIV infection with CD4 \<200/mm³. * Cardiac arrest with a poor prognosis (NSE \>60, malignant EEG, diffuse ischemia on imaging, loss of trunk reflexes). * Patients \<18 year-old * Patients under legal guardianship, curatorship, or deprived of liberty. * Ongoing pregnancy. * Patients without social security coverage.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome (ARDS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Lariboisière
RECRUITINGParis, 75010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Real-Time lung imaging Fine-Tune ventilator care for ARDS?
- Can tailored breathing support and early muscle relaxants boost survival in ARDS?
- Immune clues may unlock better ECMO care for lung failure patients
- New study aims to Fine-Tune ventilator strategies for ARDS patients
- Can the right dose and timing of steroids save more lives in ARDS?
- New inflatable cushion could revolutionize ICU patient repositioning